Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hepatology
•
Liver Diseases of Pregnancy
In what scenario do you continue surveillance of benign liver tumors, e.g., hepatocellular adenoma, in pregnant patients?
Related Questions
What management considerations do you keep in mind in the management of pregnant patients with autoimmune liver disease?
How do you approach fertility/family planning and counseling in patients with end-stage liver disease?
Do you always consider ADPCKD or ARPCKD in a patient who is incidentally found to have liver and renal cysts?
How do you utilize the Sustained Alcohol Use Post-Liver Transplant (SALT) score on surveillance for alcohol use for patients after liver transplant?
How do you utilize urine sodium and potassium levels and ratios in diuretic optimization in patients with ascites?
What kind of monitoring do you choose in patients at risk for reactivation of hepatitis B who are on immunosuppression?
Having gone through multiple iterations, what MELD updates/considerations should we anticipate in the future?
What factors do you consider when deciding to treat IgA nephropathy with immunosuppression in a patient with cirrhosis, given the possibility that IgA nephropathy could be secondary to cirrhosis?
In what clinical scenario do you initiate the use of ileal bile acid transport (IBAT) inhibitors in the management of cholestatic liver disease?
Given that cardiovascular disease is the top cause of morbidity/mortality in patients with MASLD, do you perform any additional screening and/or testing for these patients to minimize this impact?
